GAN Clinical Trials

285 recruitingLast updated: May 21, 2026

There are 285 actively recruiting gan clinical trials across 56 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Early Phase 1, Phase 4. Top locations include Philadelphia, Pennsylvania, United States, Boston, Massachusetts, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


GAN Trials at a Glance

285 actively recruiting trials for gan are listed on ClinicalTrialsFinder across 6 cities in 56 countries. The largest study group is Not Applicable with 82 trials, with the heaviest enrollment activity in Philadelphia, Boston, and Houston. Lead sponsors running gan studies include National Cancer Institute (NCI), Peking Union Medical College Hospital, and Second Affiliated Hospital, School of Medicine, Zhejiang University.

About GAN Clinical Trials

Looking for clinical trials for GAN? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new GAN trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about GAN clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 285 trials

Recruiting
Phase 3

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled235 locationsNCT06935357
Recruiting
Not Applicable

Organoid Models of Hepatocellular Carcinoma

SurgeryHepatocellular CarcinomaOrganoids+3 more
Fondazione Policlinico Universitario Agostino Gemelli IRCCS150 enrolled1 locationNCT06929845
Recruiting
Phase 1

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Malignant Neoplasm of Bone and Articular CartilageMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Independent (Primary) Multiple Sites+7 more
M.D. Anderson Cancer Center44 enrolled1 locationNCT03093909
Recruiting

Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA

Familial Isolated Pituitary AdenomaAcromegalyGigantism+3 more
Barts & The London NHS Trust10,000 enrolled3 locationsNCT00461188
Recruiting
Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NeuroblastomaGanglioneuroblastoma, Nodular
National Cancer Institute (NCI)478 enrolled178 locationsNCT06172296
Recruiting
Phase 3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
National Cancer Institute (NCI)1,875 enrolled404 locationsNCT05675410
Recruiting

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

ProlactinomaCushing DiseasePanhypopituitarism+1 more
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2,000 enrolled1 locationNCT00001595
Recruiting
Phase 1Phase 2

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

ParagangliomaPheochromocytomaMeningioma+4 more
Perspective Therapeutics300 enrolled19 locationsNCT05636618
Recruiting
Phase 2

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Immune DysregulationPrimary Immune Regulatory DisorderChronic Granulomatous Disease+12 more
Paul Szabolcs25 enrolled1 locationNCT07284641
Recruiting
Phase 3

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Pyoderma Gangrenosum
Boehringer Ingelheim90 enrolled97 locationsNCT06624670
Recruiting

Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies

Mortality in Sickle CellSickle Cell Cardiopulmonary ComplicationsSickle Cell Organ Damage+2 more
National Heart, Lung, and Blood Institute (NHLBI)200 enrolled1 locationNCT05213572
Recruiting
Early Phase 1

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07586267
Recruiting
Not Applicable

The RECOVER Study - Postpartum Recovery of Pelvic Floor Structures and the Impact of Early Rehabilitation

Pelvic organ prolapse (POP)Urinary IncontinencePelvic Floor Muscle Training+5 more
Vastra Gotaland Region380 enrolled2 locationsNCT07430865
Recruiting

Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types

Diagnosis of Cancer of Various Organs
ClearNote Health20,000 enrolled1 locationNCT03869814
Recruiting
Phase 4

Pediatric Long-Term Follow-up and Rollover Study

Neurofibromatosis Type 1GlioblastomaAnaplastic Astrocytoma+20 more
Novartis Pharmaceuticals165 enrolled55 locationsNCT03975829
Recruiting
Phase 2

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Pancreatic Neuroendocrine TumorVon Hippel-Lindau DiseasePheochromocytoma/Paraganglioma+2 more
Merck Sharp & Dohme LLC322 enrolled84 locationsNCT04924075
Recruiting

GYNEMESH PS Mesh Post Marketing Clinical Follow-Up Study

pelvic organ prolapse
Ethicon, Inc.100 enrolled3 locationsNCT04829058
Recruiting

Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry

pelvic organ prolapseStress Urinary Incontinence
Ethicon, Inc.1,000 enrolled10 locationsNCT04829175
Recruiting
Phase 2

A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

GM2 GangliosidosisNiemann-Pick Type C Disease
Azafaros A.G.21 enrolled3 locationsNCT07399704